Bioventus Inc
NASDAQ:BVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Matterport Inc
NASDAQ:MTTR
|
US |
|
Nextera Energy Partners LP
NYSE:NEP
|
US |
|
S
|
Solarvest Holdings Bhd
KLSE:SLVEST
|
MY |
|
Group Five Pipe Saudi Ltd
SAU:9523
|
SA |
|
Inageya Co Ltd
TSE:8182
|
JP |
Bioventus Inc
Total Equity
Bioventus Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bioventus Inc
NASDAQ:BVS
|
Total Equity
$184.1m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Total Equity
$911.5m
|
CAGR 3-Years
6%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Total Equity
$2.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
14%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Total Equity
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Total Equity
$1.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Total Equity
$1.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
Bioventus Inc
Glance View
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
See Also
What is Bioventus Inc's Total Equity?
Total Equity
184.1m
USD
Based on the financial report for Dec 31, 2025, Bioventus Inc's Total Equity amounts to 184.1m USD.
What is Bioventus Inc's Total Equity growth rate?
Total Equity CAGR 5Y
5%
Over the last year, the Total Equity growth was 24%. The average annual Total Equity growth rates for Bioventus Inc have been -17% over the past three years , 5% over the past five years .
